Siemens Healthineers: Innovation Accelerates, but the Market Wants Evidence

Despite unveiling new PET/MR scanner and AI stroke tech, Siemens Healthineers' stock lingers near lows as diagnostics revenue falls 6.5% and growth guidance is cut.

The medical technology company is making waves on two fronts — cancer diagnostics and stroke care — yet its stock continues to drift near the lows. Siemens Healthineers unveiled a suite of nuclear medicine products at the SNMMI annual meeting in Los Angeles while simultaneously securing FDA clearance for its Biograph One PET/MR scanner and forging a clinical partnership aimed at transforming stroke treatment. The technology pipeline is arguably stronger than it has been in years, but investors remain focused on a different story: a shrinking earnings forecast and a diagnostics division that is bleeding revenue.

At the SNMMI booth, the group displayed its Biograph Trinion.X PET/CT system, the Biograph Vision Quadra for large-field-of-view imaging, the Symbia Pro.specta in a theranostics configuration, and the Biograph One for combined PET/MR scanning. Underlying the hardware is an integrated strategy that ties together radiopharmaceutical production — inherited from PETNET Solutions and Advanced Accelerator Applications Molecular Imaging — with digital workflow software such as syngo.via. The concept is sound: in nuclear medicine, diagnosis, therapy planning and radiopharma are converging rapidly. But the market is asking a tougher question — can the portfolio deliver the growth that a 4.5% to 5.0% comparable revenue guidance implies?

Meanwhile, the collaboration with Cercare Medical targets one of the most time-critical conditions in medicine. The Cone-Beam CT perfusion technique allows physicians to analyse blood flow disturbances in the brain directly inside the catheter lab, bypassing the need for a separate CT scanner. That could shave crucial minutes off the decision-to-treatment window. The technology combines real-time imaging with AI-driven software that automatically marks critical areas. Siemens Healthineers is betting that this kind of workflow innovation, paired with the recently FDA-cleared Biograph One and the development of Photon-Flash ultra-fast radiotherapy, will eventually lift the top line. For now, the pipeline is a story of promise rather than profit.

The financial reality tells a more split narrative. In the second quarter of fiscal 2026, the Imaging segment delivered like-for-like growth of 6.1% and an adjusted EBIT margin of 22.4%. Precision Therapy advanced 4.7% and posted a margin of 13.3%. Diagnostics, however, swung the other way: comparable revenues fell 6.5%, and the adjusted EBIT margin scraped in at 0.9%. Siemens Healthineers blames structural market changes in China for the damage. On a group level, comparable revenue growth reached 3.1% with an adjusted EBIT margin of 14.7% — a figure weighed down by tariffs and currency effects.

The guidance cut announced earlier this year overhangs the stock like a storm cloud. For the full 2026 fiscal year, comparable revenue growth is now seen at 4.5% to 5.0%, down from the previous range of 5% to 6%. Adjusted diluted earnings per share are expected to land between EUR 2.20 and EUR 2.30, versus the earlier target of up to EUR 2.40. The market has not forgiven the downgrade.

The share price reflects the scepticism. At EUR 34.60, the stock sits barely 4% above its 52-week low from mid-May. The rival data point of EUR 34.91 from a separate publication shows the share has lost 21.44% since the start of the year and is nearly 30% below the 52-week peak of EUR 49.86. The relative strength index hovers around 71 on both readings, signalling short-term overbought conditions — a technical warning that even the modest recent bounce may be fragile.

Analysts remain broadly positive on the name, and the demographic tailwind is undeniable: stroke and cancer incidence rise with age. But the market wants to see the Diagnostics division stabilise before it rewards any of the innovation. The third-quarter numbers will be the next test of whether the imaging and theranostics strength is enough to offset the Chinese headwind. Until then, Siemens Healthineers is a company with impressive technology on display and a stock that is still waiting for its catalyst.